These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 36109095)
1. Progressive loss of the thyroid tissue integrity visualised by serial CT scans. Koyama H; Hattori R; Sagawa H; Tanaka T BMJ Case Rep; 2022 Sep; 15(9):. PubMed ID: 36109095 [TBL] [Abstract][Full Text] [Related]
2. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis. Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030 [TBL] [Abstract][Full Text] [Related]
3. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531 [TBL] [Abstract][Full Text] [Related]
5. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965 [TBL] [Abstract][Full Text] [Related]
7. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab. Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271 [No Abstract] [Full Text] [Related]
8. An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy. Cuzzocrea M; Paone G; Ceriani L; Giovanella L Clin Nucl Med; 2022 Mar; 47(3):253-254. PubMed ID: 34690289 [TBL] [Abstract][Full Text] [Related]
9. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185 [TBL] [Abstract][Full Text] [Related]
10. Destructive thyroiditis followed by hypothyroidism associated with infliximab therapy. Ozkan C; Altinova AE; Cerit ET; Yalcin MM; Toruner FB; Akturk M; Cakir N Endocr Pract; 2014 Nov; 20(11):e207-10. PubMed ID: 25100375 [TBL] [Abstract][Full Text] [Related]
11. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database. Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083 [TBL] [Abstract][Full Text] [Related]
12. Evolution of thyroid 127I stores measured by X-ray fluorescence in subacute thyroiditis. Fragu P; Rougier P; Schlumberger M; Tubiana M J Clin Endocrinol Metab; 1982 Jan; 54(1):162-6. PubMed ID: 7054213 [TBL] [Abstract][Full Text] [Related]
13. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency. Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202 [TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of thyroid CT values in various thyroid conditions. Kaneko T; Matsumoto M; Fukui K; Hori T; Katayama K J Comput Tomogr; 1979 Mar; 3(1):1-4. PubMed ID: 262204 [TBL] [Abstract][Full Text] [Related]